Flexible CDMO partnerships, cutting-edge technology, and scientific expertise to propel your cell therapy forward. From pre-clinical support to Phase I-III trials and commercial enablement, we unlock your cell therapy with a seamless, science-driven approach to development, manufacture, and release of product.

2025年3月17日 · BioCentriq rebrands as Made Scientific, a CDMO dedicated to accelerating cell therapy development and commercialization with cutting-edge technology and flexible partnerships.

Through collaboration and innovation, BioCentriq is dedicated to evaluating emerging process technology and platforms to create the next generation of manufacturing solutions. BioCentriq team members are actively involved in efforts to progress CAR-T manufacturing methods with the goal of increasing process robustness and product quality.

2025年3月18日 · BioCentriq has announced its rebrand as Made Scientific, a move aimed at reinforcing its commitment to accelerating cell therapy development and commercialization. The new identity, which stands…

2024年1月3日 · The funding round marks a significant milestone in BioCentriq's mission to accelerate delivery of innovative cell therapies by translating, optimizing, and scaling processes for GMP manufacture.

2024年12月17日 · Operating from two U.S.-based manufacturing facilities, BioCentriq combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC ...

2024年12月18日 · By offering both standardized platform solutions and fully customizable services, including hybrid and person-in-plant operations, dedicated cleanroom capacity, and other flexible service arrangements, BioCentriq empowers its clients to advance innovative, personalized therapies with unparalleled precision and efficiency.

2024年6月1日 · BioCentriq Value Proposition Patient-centricity is our commitment. Delivering excellence is our service promise. Global CDMO specializing in cell banking and autologous and allogeneic cell therapies. Proven track record developing, manufacturing, and releasing GMP drug

PRINCETON, N.J., March 17, 2025 /PRNewswire/ -- BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a company rebrand and its new launch...

BioCentriq is the cell and gene therapy development and manufacturing center. Leveraging state-of-the-art facilities, cutting-edge technologies, and a team of seasoned professionals, the company has a demonstrated history of effectively transferring, developing and manufacturing GMP drug products for clinical trial use.